The global market for gram positive bacterial infections has been examined in a recent market intelligence report by Transparency Market Research. The report, titled “Gram-Positive Bacterial Infections Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” gives a thorough overview of the past and present state of the market and its crucial elements, as well as presents a forward-looking perspective for the market for the period between 2014 and 2020.
Download Report Brochure For More Industry Insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2746
Bacteria are an essential class of micro-organisms that can cause various infections and diseases in humans and animals. Bacteria are divided into two categories based on gram stGram-positive Bacterial Infection Marketaining test: gram-negative and gram-positive market. Gram-positive bacteria represent a major class of bacteria that are responsible for causing a variety of chronic and acute diseases.
The report states that the global market for gram positive bacterial infections will exhibit significant growth over the report’s forecast period. Growth will be driven by the rising incidence of fatal bacterial infections, favorable government initiatives aimed at spreading awareness regarding preventive measures and treatment options, and the significant rise in research and development activities aimed at devising effective drugs. Rising awareness among consumers and increased expenditure on healthcare are also propelling the global gram-positive bacterial infections market.
The extensive R&D practices in the field of gram-positive bacterial infections have led to the development of a large number of drugs and formulations in the market, some of which are already out in the market and some are undergoing clinical trials. Some of the major pipeline drugs in the global gram positive bacterial infections market are LTX-109, XF-70, PYN-6, TD-1607, and RX-P792.
For the purpose of the study, the global gram-positive bacterial infections market has been examined based on certain criteria, such as bacterial class, disease caused by bacteria, antibacterial drug, and geography.
On the basis of bacterial class, the market can be examined for clostridium, lactobacillus, bacillus, streptococcus, enterococcus, staphylococcus, actinomyces, listeria, mycobacterium, and others. Based on the type of disease caused, the market for gram-positive bacterial infections can be examined for newborn meningitis, tuberculosis and other respiratory diseases, acne, anthrax, and others.
On the basis of antibacterial drugs, the market can be examined for clavulanic acid (Augmentin), B-lactum antibiotics (Penicillin), polypeptides (Bacitracin), glycopeptides (Vancomycin), aminoglycosides (Streptomycin), tetracycline, and chloramphenicol.
On the basis of geography, the market has been segmented into North America, Asia Pacific, Europe, and Rest of the World. Presently, developed regions such as North America and Europe are the dominant regions in the global gram-positive bacterial infections market, majorly owing to high awareness and availability of excellent healthcare facilities. However, the market is expected to expand at a substantial pace in Asia Pacific and the Rest of the World owing to rising awareness and increased expenditure on healthcare.
Some of the major vendors operating in the global gram-positive bacterial infections market are TAXIS Pharmaceuticals, Inc., Cubist Pharmaceuticals, GSK plc, Basilea Pharmaceuticals Ltd., Pfizer, Inc., Novabiotics Ltd., Theravance, Inc., and Aphios Corporation.